2011 Annual Shareholder Meeting The 2011 Annual Meeting of Shareholders of DATATRAK International, Inc., will be held at 10:00 a.m., local time, on Wednesday, August 10, 2011 at our DATATRAK Clinical and Consulting Services (DCCS) headquarters located at 2601 Weston Parkway, Suite 101, Cary, North Carolina 27513. For more information, please visit our Investor Information [...]

ASCO Annual ’11 Meeting DATATRAK will be exhibiting in Booth 19123 at the American Society of Clinical Oncology (ASCO) Annual Meeting. Individuals attending the meeting are encouraged to visit the booth to learn how DATATRAK’s unified technology approach safely accelerates your oncology drug development time lines. DATATRAK will be demonstrating its oncology-specific solution, which utilizes [...]

4th Annual Clinical Forum in Lisbon DATATRAK will be exhibiting in Booth 12 from the 11th – 13th of October 2010 at the Lisboa Congress Centre. Visit the booth to see how DATATRAK ONE™ can assist you in delivering your clinical trials with safety, simplicity and speed while reducing not only your technology budgets but [...]

46th Annual Meeting of the American Society of Clinical Oncology (ASCO) The American Society of Clinical Oncology (ASCO) Annual Meeting will be held at McCormick Place in Chicago, IL June 4-8 and focus on Advancing Quality through Innovation. More than 30,000 cancer specialists from around the world will gather at the meeting to discuss the [...]

eClinical Solutions for Studies in Israel Seminar DATATRAK and PFC Pharma Focus will co-sponsor a seminar in Tel Aviv, Israel, focusing on eClinical solutions for the clinical trials industry. The topics addressed at the seminar will identify and decipher the challenges, costs and obstacles customarily encountered in implementing and integrating electronic data capture (EDC) and [...]

CROss Alliance Summit 2009 We will be attending the CROss Alliance Summit in October. Nowadays, more than ever due to the world financial crisis, projects with new molecular entities are often not economically viable for relevant sectors of pharma companies because of high risk or high budget. Old drugs could regain their value with the [...]